European Commission approves Agamree (vamorolone) to treat Duchenne muscular dystrophy

The European Medicines Agency (EMA) acknowledged clinically important safety benefits of Agamree with regards to maintaining normal bone metabolism, density and growth compared to standard of care corticosteroids, alongside similar efficacy . In addition, patients who switched from a standard of care corticosteroid to Agamree maintained the efficacy benefit while recovering their growth and bone health.

This makes Agamree the first and only medicinal product to have received full approval in the EU and, following FDA approval in October, the first authorized treatment in both the U.S. and EU to treat patients with DMD.

The approval by the EC was based on data from the positive pivotal VISION-DMD study and three open-label studies in which vamorolone was administered at doses between 2 and 6 mg/kg/day for a total treatment period of up to 30 months. In the pivotal VISION-DMD study, boys treated with vamorolone on average maintained growth similar to those treated with placebo, whilst those treated with prednisone on average experienced growth stunting. Patients who switched from prednisone to vamorolone after 24-weeks were, on average, able to resume growing in height over the remainder of the study.

Unlike corticosteroids, vamorolone did not result in a reduction of bone metabolism as measured by bone biomarkers, nor in a significant reduction of bone mineralization in the spine as measured by Dual Energy X-Ray Absorptiometry (DXA) after 48 weeks in the clinical studies.